Related Experiment Video

Updated: Mar 6, 2026

A Phenotyping Regimen for Genetically Modified Mice Used to Study Genes Implicated in Human Diseases of Aging
09:37

A Phenotyping Regimen for Genetically Modified Mice Used to Study Genes Implicated in Human Diseases of Aging

Published on: July 14, 2016

8.8K

[The pharmacogenomics of CFH Y402H and wet age-related macular degeneration]

L L Chen1, Y Y Chen

  • 1Department of Ophthalmology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China.

[Zhonghua Yan Ke Za Zhi] Chinese Journal of Ophthalmology
|March 7, 2017
PubMed

Insights

Genetic factors influence age-related macular degeneration (AMD). The CFH Y402H gene polymorphism may affect treatment outcomes for wet AMD, impacting therapies like photodynamic therapy and anti-VEGF.

Area of Science:

  • Ophthalmology
  • Genetics
  • Pharmacogenomics

Background:

  • Age-related macular degeneration (AMD) is a primary cause of irreversible vision loss in individuals over 50.
  • Genetic factors, particularly the complement factor H (CFH) gene, are significantly implicated in AMD development.
  • The CFH Y402H polymorphism has garnered substantial research interest due to its association with AMD.

Purpose of the Study:

  • To review the current research on the pharmacogenomics of the CFH Y402H polymorphism in the context of wet AMD treatment.
  • To explore how CFH Y402H genotypes may influence the efficacy of different therapeutic interventions for wet AMD.

Main Methods:

  • Literature review of studies investigating the pharmacogenomics of CFH Y402H in wet AMD.
  • Analysis of research findings on the correlation between CFH Y402H genotypes and treatment outcomes.

Main Results:

  • The CFH Y402H genotype is associated with variations in treatment response.
  • Specific CFH Y402H genotypes may predict differential outcomes for photodynamic therapy (PDT) and anti-vascular endothelial growth factor (anti-VEGF) treatments.

Conclusions:

  • The CFH Y402H polymorphism is a relevant pharmacogenomic factor in wet AMD.
  • Understanding CFH Y402H status could potentially personalize and optimize treatment strategies for wet AMD patients.

Keywords:
Complement factor HMacular degenerationPharmacogenetics

More Related Videos

Author Spotlight: Overcoming Anti-VEGF Resistance Through Advanced Vascular Morphology Assessment in Choroidal Neovascularization05:14

Author Spotlight: Overcoming Anti-VEGF Resistance Through Advanced Vascular Morphology Assessment in Choroidal Neovascularization

Published on: August 11, 2023

1.6K
Author Spotlight: Understanding Age-Related Macular Degeneration Pathophysiology with QAF Workflow08:54

Author Spotlight: Understanding Age-Related Macular Degeneration Pathophysiology with QAF Workflow

Published on: May 26, 2023

2.2K

Related Concept Videos

Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
55
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
76
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes01:28

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450...
70
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
56
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
74
Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
65